Efficacy and Safety of Novosis Putty for Degenerative Lumbar Disease

Sponsor-initiated Clinical Study to Evaluate the Efficacy and Safety of Novosis Putty for Bone Fusion in Patients Requiring Posterior Instrumentation and Transforaminal Lumbar Interbody Fusion Due to Degenerative Lumbar Disease

This clinical study aims to evaluate the efficacy and safety of NOVOSIS PUTTY for bone fusion in patients requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.

Study Overview

• Status: Active, not recruiting
• Conditions: Degenerative Lumbar Diseases
• Intervention / Treatment: Device: Bone graft materials and rhBMP-2

Detailed Description

The Subject is a patient requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.

This clinical study aims to compare and evaluate the efficacy and safety of three dose groups of NOVOSIS PUTTY for bone fusion compared to the autologous bone in patients requiring posterior instrumentation and TLIF in the single level between L2 and S1(L2-S1) due to degenerative lumbar disease.

• Control Group (n=12): Local autologous bone
• Experimental Group 1 (n=12): Dose 1
• Experimental Group 2 (n=12): Dose 2
• Experimental Group 3 (n=12): Dose 3

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Severance Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult aged ≥ 22 to ≤ 80 years
• Subjects whose skeletal maturation are confirmed by showing the result of Risser stage 5 in Risser classification, the Plain Radiography
• Subjects diagnosed with disc degeneration in the single level (L2-S1) lumbar spine along with spondylolisthesis of Meyerding grade 1 (degree of translocation: 0- <25%) or 2 (degree of translocation: 25- <50%) based on the results of radiological examination (CT, MRI, X-ray).
• Subjects with an ODI (Oswestry Disability Index) score of ≥ 35/100 at screening
• Subjects who were treated with non surgical treatment/therapy for at least 3 months, but were judged to have failed treatment by the investigator
• Subjects who are willing to participate in the study, comply with treatment and procedures, and visit the hospital for all observational evaluations
• Subjects who voluntarily signed the informed consent form after hearing the explanation on objectives and methods of this study

Exclusion Criteria:

• Subjects who have a history of medical device application (spinal instrumentation, for example, anterior disc replacement, interspinous device) to the target site or interbody fusion
• Subjects who are considered that the symptoms occurring in the lumbar region are not occurred by disc degeneration
• Subjects with active malignancy
• Subjects with a documented history of drug abuse (e.g., psychotropic drugs including narcotic analgesics and drugs with high dependence such as alcohol) within the last 6 months
• Subjects with a history of endocrine or metabolic disorders known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehler Danlos disease, or osteogenesis imperfecta)
• Subjects with BMI ≥ 35
• Subjects with spondylolis thesis/retrolisthesis with ≥ Grade 3 in the target level
• Subjects with a local acute infection at the current surgical site or active systemic infection (e.g., viral infections such as AIDS, HIV or hepatitis)
• Subjects with a history of metabolic or endocrine diseases known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers Danlos disease, osteogenesis imperfecta, fibrous dysplasia, etc.)
• Subjects with osteoporosis with a mean lumbar spine T-score of ≤ 2.5 on the DEXA bone density test and with a history of osteoporotic fractures (wrist fractures, femur fractures, lumbar spine fractures, etc.)
• Subjects who need to administer drugs that inhibit bone metabolism within 2 weeks after surgery, or Subjects who need to receive post operative drugs that are expected to interfere with bone fusion, such as steroids
• Subjects who smoke ≥ 20 cigarettes a day
• Subjects with autoimmune disease
• Subjects who were exposed to rhBMP 2 in the past
• Subjects who require to get fusion of two or more vertebral levels
• Subjects who have a pseudoarthrosis after previous fusion
• Subjects who had a history of at least one non fusion spinal surgery on the level to be operated
• Subjects who are considered to have a disease that hinders the accurate evaluation (e.g., neuromuscular disease, serious psychiatric disease) at the discretion of the investigator
• Subjects who are pregnant at screening or who are planning to become pregnant during the study participation period
• Subjects who are currently lactating or who are planning to lactate during the study
• Subjects who participated in studies for other drugs, biologics, or medical devices within 6 months from the date of surgery
• Subjects who are in a difficult situation to comply with study related matters

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control Group; Local autologous bone
Experimental: Experimental Group 1; Dose 1	Device: Bone graft materials and rhBMP-2; NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
Experimental: Experimental Group 2; Dose 2	Device: Bone graft materials and rhBMP-2; NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
Experimental: Experimental Group 3; Dose 3	Device: Bone graft materials and rhBMP-2; NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall bone fusion rate	Meet the definition of bone fusion based on CT and the definition of bone fusion based on X-ray simultaneously.	12 months after surgery
Overall fusion success rate	Meet all of the following conditions: Success in ODI; Overall Bone Fusion Success; Neurological Success; No serious adverse event; No re-operation	12 months after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall fusion success rate	Meet all of the following conditions: Success in ODI; Overall Bone Fusion Success; Neurological Success; No serious adverse event; No re-operation	6 and 24 months after surgery
Bone fusion rate	Bone fusion rate based on CT, X-ray	6, 12, and 24 months after surgery
Oswestry Disability Index(ODI)	Evaluate Oswestry Disability Index(ODI) score/ lowest 0(best) to highest 50(worst)	6 weeks, 3, 6, 12, and 24 months after surgery
SF-12 scores (general condition test)	Evaluate SF-12 scores / lowest 0(worst) to highest 100(best)	6 weeks, 3, 6, 12, and 24 months after surgery
Numerical Rating Scale (NRS)	Evaluate Numerical Rating Scale (NRS) scores / lowest 0(best) to highest 30(worst)	6 weeks, 3, 6, 12, and 24 months after surgery
Neurological Symptoms	Evaluate Neurological Symptoms test/ check among the 3 questions(Worsened/ Constent/Improved) best is imporved, worst is worsened	6 weeks, 3, 6, 12, and 24 months after surgery
Satisfaction rate	Evaluate Satisfaction rate score / lowest 0(worst) to highest 3(best)	6 weeks, 3, 6, 12, and 24 months after surgery

Collaborators and Investigators

• Sponsor: CGBio Inc.
• Investigators: Study Chair: Jumi Han, CGBio Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2024
• Primary Completion (Actual): June 30, 2024
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: November 26, 2024
• First Submitted That Met QC Criteria: November 28, 2024
• First Posted (Estimated): December 4, 2024

Study Record Updates

• Last Update Posted (Estimated): December 4, 2024
• Last Update Submitted That Met QC Criteria: November 28, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Keywords: TLIF; Degenerative lumbar diseases; BMP-2
• Other Study ID Numbers: B2201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No